Akari Therapeutics, Plc filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 12, 2026, reporting a widened accumulated deficit and a significant decline in total assets.

Key Highlights

  • Accumulated deficit: The company reported an accumulated deficit of $288,655 thousand as of September 30, 2026, compared to $264,550 thousand as of December 31, 2025.
  • Total assets declined: Total assets fell to $36,579 thousand at September 30, 2026, from $47,892 thousand at December 31, 2025, according to the filing.
  • Goodwill eliminated: Goodwill was $0 at September 30, 2026, down from $8,430 thousand at December 31, 2025.
  • Cash position: Cash was $5,743 thousand at September 30, 2026, compared to $5,203 thousand at December 31, 2025.
  • Shares outstanding: Ordinary shares issued and outstanding were 182,813,169,533 at September 30, 2026, up from 90,536,879,533 at December 31, 2025.
  • Total shareholders' equity: Shareholders' equity was $17,502 thousand at September 30, 2026, versus $28,328 thousand at December 31, 2025.

Akari Therapeutics Balance Sheet Shows Asset Contraction and Equity Erosion Through September 2026

According to the filing, Akari Therapeutics, Plc (NASDAQ:AKTX) reported total assets of $36,579 thousand as of September 30, 2026, a decrease from $47,892 thousand at December 31, 2025. The company disclosed that goodwill, which stood at $8,430 thousand at year-end 2025, was reduced to zero by the end of the third quarter of 2026. Other intangible assets also declined, to $30,300 thousand from $34,000 thousand over the same period.

The filing disclosed that the accumulated deficit grew to $288,655 thousand as of September 30, 2026, from $264,550 thousand at December 31, 2025, contributing to a reduction in total shareholders' equity from $28,328 thousand to $17,502 thousand. Additional paid-in capital increased to $247,428 thousand from $234,318 thousand, reflecting the substantial increase in ordinary shares issued and outstanding, which more than doubled from 90,536,879,533 to 182,813,169,533 shares over the nine-month period.

On the liabilities side, the company reported total liabilities of $19,077 thousand at September 30, 2026, down from $19,564 thousand at December 31, 2025. Accounts payable stood at $9,050 thousand, while accrued expenses rose to $3,792 thousand from $2,342 thousand. The filing noted that convertible notes, net, which were $673 thousand at year-end 2025, were $0 at September 30, 2026. As of November 12, 2026, the registrant disclosed that ordinary shares outstanding totaled 186,091,889,533. The filing contains forward-looking statements that, as the company stated, are subject to risks and uncertainties and should not be relied upon as representing the company's estimates as of any date after the filing date.

What Was Disclosed

Akari Therapeutics filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing condensed consolidated balance sheet data showing a widened accumulated deficit, reduced total assets, elimination of goodwill, and a more than doubling of ordinary shares outstanding since December 31, 2025.